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Where Next after SPACE and EVA-3S:
‘The Good, the Bad and the Ugly!’
A. Ross Naylor*
The Department of Vascular Surgery at Leicester Royal Infirmary, Leicester, UK
SPACE and EVA-3S are the latest to publish outcomes in recently symptomatic patients who were randomised to carotid
endarterectomy (CEA) or angioplasty and stenting (CAS). Contrary to expectations, both found that CAS was not ‘as
good as’ CEA, while EVA-3S found CEA to be statistically superior. Not surprisingly, these trials have aroused consider-
able controversy and many in the pro-CAS lobby have simply dismissed them as being methodologically flawed and un-
representative of contemporary CAS practice. However, to simply dismiss SPACE and EVA-3S as maverick trials is
unacceptable. Unlike the landmark ‘symptomatic’ and ‘asymptomatic’ studies, the history of randomised trials comparing
CAS and CEA has been characterised by repeated trial suspension (because of excess risk in the CAs cohort) and a system-
atic failure to achieve randomisation targets (thereby preventing any prospect of a statiscally meaningful outcome) amid
a milieu of corporate and individual conflicts of interest. SPACE and EVA-3S have certainly informed the dabate but they
have not resolved it. Two trials are actively randomising recently symptomatic patients (ICSS in Europe and CREST in
North America). Both require our support so that future guidelines are ‘evidence based’ rather than ‘marker driven’.
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how a new technique replaced a ‘gold-standard’ with-
out resorting to multi-centre, randomised trials. By
contrast, the longevity of carotid endarterectomy
(CEA) is exclusively due to it having been subjected
to detailed randomised comparison, despite surgical
opposition at the time. Four trials (ECST, NASCET,
ACAS & ACST) were pivotal in determining who
gained most (and least) from CEA.1e4 Most impor-
tantly, these guidelines were achieved with remark-
able consensus amongst surgeons, neurologists and
stroke physicians.
Unfortunately, eight randomised trials comparing
CEA with angioplasty and stenting (CAS) have failed
to establish any consensus.5e12 More worrying, this fail-
ure to provide an unambiguous answer to a seemingly
simple question has fuelled a belief that randomised
trials may never provide a definitive answer coinciden-
tal with an environment of corporate/individual
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the effect of a surgeon worrying about his/her
income.
These are, of course, provocative comments!
WALLSTENT, one of the largest randomised trials of
its era was industry sponsored. When abandoned,
with a threefold excess risk after CAS, it only reported
in abstract form.6 One is left to assume that the spon-
sors blocked its publication. Second are the sequellae
of SAPPHIRE,12 another industry sponsored trial in
predominantly asymptomatic patients that influenced
‘opinion’ more than its findings warranted.13 The first
consequence was declining recruitment into other
randomised trials as commentators hailed CAS as
the ‘safer’ or ‘preferred’ option.14 Thereafter, rivals re-
alised that one company was going to dominate the
market and so the SAPPHIRE findings were used to
justify a myriad of ‘high-risk’ stent registries in order
to promote rival stents and cerebral protection devices
(CPD). This ‘market-driven’ swing towards CAS then
caused some surgeons to fear that their income
might be threatened. It was then inevitable that the
surgeon would also become a CAS expert and join
the ‘turf-war’ with cardiologists, neuroradiologists
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46 A. R. Naylorand interventionists! However, what has gone rela-
tively unnoticed is that SAPPHIRE’s principle investi-
gator (who sold the obligatory trial CPD to the
sponsoring company) was withdrawn from present-
ing the trial’s findings to the FDA because of per-
ceived ‘financial conflicts of interest’ that later led to
his dismissal from the Cleveland Clinic amid FDA
allegations of irregularities in reporting adverse
events in clinical studies.15 Although SAPPHIRE
may remain ‘whiter than white’, this is not the way
to determine evidence based practice.
Given this background, it was inevitable that pub-
lication of SPACE and EVA-3S would court contro-
versy as the findings were clearly at odds with the
trend towards CAS.9,10 Using predefined margins of
non-inferiority, both showed that CAS was not ‘as
good as’ CEA, while EVA-3S found that CEA was sta-
tistically superior. Accordingly, CEA secured tempo-
rary respite while the pro-CAS lobby responded
with a campaign of ‘damage limitation’ with particu-
lar anger being focussed on ‘interventionist experi-
ence’ and ‘CAS methods’ in the two trials. Ironically,
this strategy of ‘discrediting the opposition’ had
been honed to perfection by surgeons two decades
earlier when the primacy of CEA was questioned!
Do we never learn?
So where to now? If CAVATAS answered nothing
else, it demonstrated to a sceptical surgical audience
that following successful CAS, three year outcomes
were probably no different to CEA.7 Accordingly,
the intervention which wins the battle of the ‘30-day
risk’ will triumph in the end. Table 1 summarises
data from the six randomised trials in recently symp-
tomatic patients. With few exceptions, each reported
30-day risks that were well in excess of those being re-
ported in the non-randomised literature. Second, four
of six trials failed to achieve their planned recruitment
(by a staggering 1803 patients in total) thereby com-
promising any realistic chance of securing statistically
valid outcomes. Third, is the very real difficulty of
comparing outcomes as CAS technology evolves
(e.g. publication year, learning curve, CPD, dual anti-
platelet therapy).
EVA-3S faces the most hostile criticism regarding
the third observation. Yet, paradoxically, EVA-3S
may represent what could happen in the ‘real world’
following implementation of CAS into routine prac-
tice, rather than seeing what happens in ‘elite’ CAS
units. De´ja` vu! The same criticism (regarding general-
isability) was levelled by neurologists in the 1990s
when surgeons were faced with the accusation that
their high-quality trial results simply reflected sur-
geon selection. To-date, CAS practitioners have never
had to address the issue of generalisability. Moreover,Eur J Vasc Endovasc Surg Vol 33, January 2007CPDs are clearly no panacea as evidenced by the
SPACE and EVA-3S findings of a 30-day death/stroke
rate of 7% when they were used. EVA-3S (like SPACE)
used proctoring, but neither the number of patients
randomised per centre, nor the previous ‘experience’
of the CAS practitioner influenced outcome. Similarly,
dual antiplatelet therapy did not influence risk, nor
did whether the patient was randomised pre February
2003 (when EVA-3S was suspended and restarted
with obligatory CPD usage) or after February 2003.
These observations will, of course, never satisfy the
ardent critic who will counter that he/she can per-
form CAS with 30-day death/stroke rates of 2e3%
or less. Not surprisingly, many surgeons make similar
claims regarding their own CEA practice. That is not
the point! It would however be interesting to know
how many of these critics participated in PASCAL
(another industry sponsored stent registry using expe-
rienced CAS interventionists) and which encountered
a 30-day death/stroke rate of 7.5% in asympto-
matic patients! Funnily enough, that registry hasn’t
published either!
In conclusion, surgeons who think that SPACE and
EVA-3S have settled the debate and restored CEA to
primacy are deluded! Similarly, those interventionists
who comfort themselves by writing off SPACE and
EVA-3S as maverick trials are also blind to reality.
The most obvious reason why the results of SPACE
and EVA-3S were poorer than SAPPHIRE is that
they randomised recently symptomatic patients, i.e.
high risk for stroke. That description could never ap-
ply to the SAPPHIRE cohort. Finally, the main reason
why ECST, NASCET, ACAS and ACST influenced
clinical practice was because they randomised large
numbers of patients. CEA and CAS will inevitably
have a complementary role. It is therefore imperative
that we support the two remaining trials that are
randomising recently symptomatic patients (ICSS in
Europe and CREST in North America).
One day it may be you who will benefit from the
best available evidence!
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